The impact of quadruple immunosuppression with OKT3 on kidney transplantation in black recipients. 1996

E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
Department of Surgery, School of Public Health, University of Illinois, Chicago 60612, USA.

BACKGROUND Black recipients of kidney transplants have been shown to have lower graft survival than other racial groups. There is ongoing controversy about the optimal immunosuppressive protocol for blacks after kidney transplantation. METHODS Five hundred-eighty-two recipients of kidney transplants performed between 1985 and 1994 were divided into three groups: (1) nonblacks who received cyclosporine and prednisone (N = 292); (2) blacks who received "quadruple" cyclosporine based immunosuppression with OKT3 induction (N = 98); and (3) blacks who received cyclosporine and prednisone only (N = 192). Patient and graft survival and incidence of acute rejection episodes were compared among the groups. RESULTS Blacks had lower graft survival when compared with nonblacks. However, in the subgroup of black recipients who received quadruple immunosuppression, graft survival at 1 year was higher and the incidence of acute rejection episodes was significantly decreased compared with blacks without induction. Graft survival and the incidence of acute rejection in blacks on quadruple therapy was comparable with nonblacks. CONCLUSIONS Our data support the principle that quadruple immunosuppression should be used routinely for black recipients of kidney transplants.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014181 Transplantation Immunology A general term for the complex phenomena involved in allo- and xenograft rejection by a host and graft vs host reaction. Although the reactions involved in transplantation immunology are primarily thymus-dependent phenomena of cellular immunity, humoral factors also play a part in late rejection. Immunology, Transplantation
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016853 Muromonab-CD3 Anti-CD3 monoclonal antibody that exerts immunosuppressive effects by inducing peripheral T-cell depletion and modulation of the T-cell receptor complex (CD3/Ti). Monoclonal Antibody OKT3,OKT3,Orthoclone OKT3,Muromonab CD3
D044383 Black People Persons having origins in any of the black racial groups of AFRICA. Note that OMB category BLACK OR AFRICAN AMERICAN is available for the United States population groups. Race and ethnicity terms, as used in the federal government, are self-identified social construct and may include terms outdated and offensive in MeSH to assist users who are interested in retrieving comprehensive search results for studies such as in longitudinal studies. African Continental Ancestry Group,Black Person,Negroid Race,Black Peoples,Black Persons,Negroid Races,People, Black,Person, Black,Persons, Black,Race, Negroid

Related Publications

E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
November 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
January 1999, The Annals of thoracic surgery,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
October 1990, Transplantation proceedings,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
October 1987, Surgery,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
February 1994, Transplantation proceedings,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
February 1989, Transplantation proceedings,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
July 1993, The American journal of the medical sciences,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
February 1989, Transplantation proceedings,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
August 2007, Transplantation,
E Benedetti, and S A Freels, and N T Coady, and E M Vasquez, and R Pollak
February 1991, Transplantation proceedings,
Copied contents to your clipboard!